secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-11-10T13:05:32+00:00
Accession:  0001213900-26-117781
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Turn Therapeutics (TTRX) posts updated investor presentation dated Nov 10, 2026; exhibit text lacks financial detail
--------------------------------------------------------------------------------

- Updated investor presentation dated November 10, 2026 released; no separate press release, earnings release or financial-data tables accompany it.
- The appended exhibit text contains only the cover slide and a forward-looking-statements safe-harbor page; no revenue, cash, pipeline or trial data is legible.
- Signed by Chief Executive Officer Bradley Burnam on November 10, 2026; company is an emerging growth company.
- No operational, clinical, financial or guidance changes are disclosed in the readable text; investors must obtain the full deck from the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026117781/0001213900-26-117781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026117781/ea0311587-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-117781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer